Generation of a Genetically Modified Chimeric Plasmodium falciparum Parasite Expressing Plasmodium vivax Circumsporozoite Protein for Malaria Vaccine Development

Yukiko Miyazaki1‡, Catherin Marin-Mogollon1‡, Takashi Imai1,2, António M. Mendes3, Rianne van der Laak4, Angelika Sturm4, Fiona J. A. Geurten1, Shinya Miyazaki1, Severine Chevalley-Maurel1, Jai Ramesar1, Surendra K. Kolli1, Hans Kroeze1, Roos van Schuijlenburg1, Ahmed M. Salman5, Brandon K. Wilder6, Arturo Reyes-Sandoval5, Koen J. Dechering4, Miguel Prudêncio3, Chris J. Janse1, Shahid M. Khan1† and Blandine Franke-Fayard1*

1 Department of Parasitology, Leiden University Medical Center, Leiden, Netherlands, 2 Department of Infectious Diseases and Host Defense, Gunma University Graduate School of Medicine, Maebashi, Japan, 3 Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal, 4 TropIQ Health Sciences, Nijmegen, Netherlands, 5 The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom, 6 Vaccine and Gene Therapy Institute, Oregon Health and Science University, Portland, Oregon, United States

Chimeric rodent malaria parasites with the endogenous circumsporozoite protein (csp) gene replaced with csp from the human parasites Plasmodium falciparum (Pf) and P. vivax (Pv) are used in preclinical evaluation of CSP vaccines. Chimeric rodent parasites expressing PfCSP have also been assessed as whole sporozoite (WSP) vaccines. Comparable chimeric P. falciparum parasites expressing CSP of P. vivax could be used both for clinical evaluation of vaccines targeting PvCSP in controlled human P. falciparum infections and in WSP vaccines targeting P. vivax and P. falciparum. We generated chimeric P. falciparum parasites expressing both PfCSP and PvCSP. These Pf-PvCSP parasites produced sporozoite comparable to wild type P. falciparum parasites and expressed PfCSP and PvCSP on the sporozoite surface. Pf-PvCSP sporozoites infected human hepatocytes and induced antibodies to the repeats of both PfCSP and PvCSP after immunization of mice. These results support the use of Pf-PvCSP sporozoites in studies optimizing vaccines targeting PvCSP.

Keywords: malaria, Plasmodium falciparum, Plasmodium vivax, circumsporozoite protein (CSP), chimeric parasites, vaccines

INTRODUCTION

Plasmodium falciparum (Pf) and P. vivax (Pv) are two major human malaria parasites that threaten public health, mainly in tropical areas. Malaria parasites are transmitted by Anopheles mosquitoes where they develop into infectious sporozoites that reside in the salivary glands. After a bite of an infected mosquito, sporozoites enter the blood stream of the mammalian host and migrate to
liver where they invade hepatocytes. Inside hepatocytes, parasites replicate to form thousands of daughter merozoites, which are released into the blood and invade erythrocytes. The pre-erythrocytic stages of *Plasmodium* parasites, i.e. sporozoites and liver stages, are attractive targets of leading malaria vaccine candidates, including RTS,S, the most advanced subunit vaccine against *P. falciparum* tested in Phase III clinical trials (Kester et al., 2009; Cohen et al., 2010; Agnandji et al., 2012; Olotu et al., 2016). RTS,S is based on the circumsporozoite protein (CSP), a major surface protein expressed by *Plasmodium* sporozoites and early liver stages which plays a critical role in sporozoite formation, invasion of mosquito salivary glands and invasion of host hepatocytes (Ménard, 2000; Sinnis and Coppi, 2007; Coppi et al., 2011). This protein contains a highly conserved central repeat region flanked by N- and C-terminal regions. B-cell responses to PfCSP target predominantly the protein’s central NANP repeat region, generating antibodies capable of protecting animal models from *Plasmodium* infection and NANP antibodies induced by RTS,S immunization are associated with clinical protection (White et al., 2013; Foquet et al., 2014; Sack et al., 2014; Triller et al., 2017). CSP from *P. vivax* also contains an immunogenic central repeat region with two major PvCSP alleles, VK210 and VK247 considered as important targets for a vaccine (Yadava and Waters, 2017). So far pre-erythrocytic subunit vaccines targeting CSP, including RTS,S, have shown low to modest protective efficacy in clinical trials and in field studies (Agnandji et al., 2015; Hoffman et al., 2015; Clemens and Moorthy, 2016; Long and Zavala, 2016; Olotu et al., 2016; Healer et al., 2017; Mahmoudi and Keshavarz, 2017) emphasizing the need to improve CSP-based vaccination approaches which requires efficient preclinical and clinical evaluation of different vaccines. Clinical evaluation of *P. falciparum* vaccines is greatly aided by the ability to vaccinate individuals and then examine vaccine efficacy in controlled human malaria infections (CHMI) (Sauerwein et al., 2011; Spring et al., 2014; Bijker et al., 2016; Stanisic et al., 2018). Although CHMI for *P. vivax* has been developed (Arrévalo-Herrera et al., 2016; Bennett et al., 2016; Payne et al., 2017; Hall et al., 2019), the lack of a continuous *in vitro* culture system for *P. vivax* blood stages limits the availability of *P. vivax* sporozoites for clinical human infections. In addition, since *P. vivax* forms dormant hypnozoites in the liver, which can cause infection relapses, safe and effective means for clearance of hypnozoites are essential for *P. vivax* CHMI studies (Payne et al., 2017).

In multiple preclinical studies, the evaluation of the efficacy of CSP-based vaccines and anti-CSP antibodies has been performed using chimeric rodent malaria parasites expressing CSP from either *P. falciparum* or *P. vivax* (Espinosa et al., 2013; Gimenez et al., 2017; Salman et al., 2017; Vijayan et al., 2017; de Camargo et al., 2018; Marques et al., 2020). The availability of comparable chimeric *P. falciparum* parasites expressing PfCSP would permit the analysis of protective efficacy of PvCSP-based vaccines in clinical studies using *P. falciparum*-based CHMI, bypassing the need for *P. vivax* sporozoite production and hypnozoite elimination. However, in contrast to efficient PfCSP expression and sporozoite production in chimeric rodent parasites, we found that chimeric *P. falciparum* lines with the PfCSP gene replaced by PvCSP, failed to produce salivary gland sporozoites, indicating that PfCSP cannot fully complement the role of PfCSP in *P. falciparum* sporozoite formation (Marin-Mogollon et al., 2018). To develop chimeric *P. falciparum* sporozoites expressing PvCSP, we therefore aimed at generating a chimeric *P. falciparum* line expressing both the endogenous PfCSP and an engineered PvCSP. It has been shown that introducing the *P. falciparum* csp gene as an additional copy into the genome of the rodent parasite *P. berghei* (Pb) results in development of viable and infective sporozoites, expressing both PbCSP and PfCSP in pre-erythrocytic stages (Meneses et al., 2018a; Meneses et al., 2018b; Reuling et al., 2020). We used CRISPR/Cas9 gene editing to introduce a chimeric Pvcsp gene, containing repeats of both the VK210 and VK247 alleles, into the Pfp47 locus of the *P. falciparum* NF54 genome. We found that these Pf-PvCSP chimeric *P. falciparum* parasites produced viable, motile sporozoites expressing both PfCSP and chimeric PvCSP at the sporozoite surface that are infectious to primary human hepatocytes. Immunization of mice with these sporozoites resulted in induction of antibodies against the repeats of both PfCSP and chimeric PvCSP. These results not only show promise for the use of Pf-PvCSP sporozoites in clinical CHMI studies for optimization of vaccines targeting PvCSP, but also suggest that such chimeric sporozoites can be used in whole, attenuated sporozoite vaccination approaches, capable of inducing cross-protective immune responses against both *P. falciparum* and *P. vivax*.

**MATERIALS AND METHODS**

**In Vitro Cultivation of *P. falciparum* Blood Stages**

Wild type *P. falciparum* NF54 (WT NF54) parasites (Ponnudurai et al., 1981) were obtained from the Radboud University Medical Center (Nijmegen, The Netherlands). Parasites were cultured in RPMI-1640 culture medium supplemented with L-glutamine and 25mM HEPES (Gibco Life Technologies), 50 mg/L hypoxanthine (Sigma), 0.225% NaHCO₃ and 10% human serum at a 5% hematocrit under 4% O₂, 3% CO₂ and 93% N₂ gas-conditions at 75 rpm at 37°C in a semi-automated culture system (Infers HT Multitron and Watson Marlow 520U) as previously described (Mogollon et al., 2016). Fresh human serum and human red blood cells (RBC) were obtained from the Dutch National Blood Bank (Sanquin Amsterdam, the Netherlands; permission granted from donors for the use of blood products for malaria research and microbiology tested for safety). Production of genetically modified parasites and characterization of these parasites throughout their life cycle, including mosquito transmission, was performed under GMO permits IG 17-230 II-k and IG 17-135 III.

**Laboratory Animals and Ethics Statement**

Female C57BL/6Jco mice (6–7 weeks; Charles River, NL) were used. All animal experiments were granted a licence by the Competent Authority after an advice on the ethical evaluation by the Animal
Experiments Committee Leiden (AVD1160020171625). All experiments were performed in accordance with the Experiments on Animals Act (Wod, 2014), the applicable legislation in the Netherlands and in accordance with the European guidelines (EU directive no. 2010/63/EU) regarding the protection of animals used for scientific purposes. All experiments were performed in a licenced establishment for the use of experimental animals (LUMC). Mice were housed in individually ventilated cages furnished with autoclaved aspen woodchip, fun tunnel, wood chew block and nestlets at 21 ± 2°C under a 12:12 h light-dark cycle at a relative humidity of 55 ± 10%.

Anopheles Rearing
Mosquitoes from a colony of Anopheles stephensi (line Nijmegen SDA500) were used. Larval stages were reared in water trays at a temperature of 28 ± 1°C and a relative humidity of 80%. Adult females were transferred to incubators with a temperature of 28 ± 0.2°C and a relative humidity of 80%. For the transmission experiments, 3- to 5-day-old mosquitoes were used.

Generation of the Chimeric Pf-PvCSP Parasites
Chimeric P. falciparum parasites expressing both PfCSP and chimeric PvCSP (PvCSP-chi), were generated using the previously described pLf0019 construct (Mogollon et al., 2016) (Figure S1), containing the cas9 gene, together with the gRNA-donor DNA containing plasmid, pLf0109, targeting Pfpsi47 which contains the Pvcsp-chi expression cassette. The pLf0019 construct contains a blasticidin (bsd) drug-selectable marker cassette and the pLf0109 gRNA-donor DNA construct contains a hdhfr-ycfu drug-selectable marker cassette for selection with WR99210 and 5-fluorocytocine (5-FC) (Figure S1). To generate pLf1019, the plasmid pLf0047 (Marin-Mogollon et al., 2019), containing two homology regions and a gRNA expression cassette targeting Pfpsi47 (PF3D7_1346800), was modified by introducing a Pvcsp-chi expression cassette, which was commercially synthesized (Integrated DNA Technologies, Inc; see Figure S2). This Pvcsp-chi expression cassette contains a codon-optimized Pvcsp open reading frame (ORF) containing the N- and C-terminal regions of the Pvcsp VK210 allele that flank a chimeric repeat sequence comprising repeats of both the VK210 allele (three times the repeat GDRADGQPA/GDRAAGQPA) and the VK247 allele (three times the repeat ANGAGNQPG/ANGAGDQPG). The ORF of Pvcsp-chi is flanked by EcoRV/EcoRI restriction sites and cloned into pLf0040 (cut EcoRV/EcoRI) (Marin-Mogollon et al., 2018) which contains 967bp of the promoter regions of Pfpsi47 (PF3D7_0304600) and 917bp of 3’UTR of Pfcsp resulting in intermediate plasmid T24 (Figure S1). This plasmid was digested with ApaI/SaciI to obtain the complete Pvcsp-chi expression cassette containing the Pfcsp promoter, the Pvcsp-chi ORF with the chimeric VK210/VK247 repeats, and the Pfcsp 3’UTR. This expression cassette was inserted into vector pLf0047 (Figure S1) using the same restriction enzymes (ApaI/SaciI) resulting in the final construct pLf0109. Plasmids for transfection were isolated from 250 ml cultures of Escherichia coli XL10-Gold Ultracompetent Cells (Stratagene, NL) by maxi-prep (PureYield™ Plasmid Maxiprep System (Promega, NL) to generate 25–50 µg of DNA used per transfection. Transfection of WT PfNF54 parasites was performed using the ‘spontaneous uptake method’ as previously described (Miyazaki et al., 2020). Briefly uninfected RBC (300 µl of packed RBCs) were transfected with the constructs pLf0019 and pLf0109 (a mixture of 25 µg of each circular plasmid in 200 µl cytomix) using the Gene Pulser Xcell electroporator (BioRad) with a single pulse (310 V, 950 µF). Subsequently, the transfected RBCs were washed with complete RPMI1640 medium and mixed with WT PfNF54 infected RBC (iRBC) with a parasitemia of 0.5% and a hematoctrit of 5%. These cells were transferred into a 10 ml culture flask and the cultures were maintained under standard conditions in the semi-automated culture system (Mogollon et al., 2016). Selection of transfected parasites was performed by applying double-positive drug pressure from day 3 after transfection using the drugs WR99210 (2.6 nM) and BSD (5 µg/ml). The positive drug pressure was maintained until parasites were detectable in thin blood-smears (at day 15 after transfection). Subsequently, the parasites were maintained in drug-free medium for 2–4 days until the parasitemia reached over 10%, followed by applying negative selection by addition of 5-FC (1 µM) as described before (Mogollon et al., 2016) in order to eliminate parasites that retained the donor DNA construct as episomal plasmid and to enrich for the transfected parasites containing the donor DNA integrated into the genome. Negative drug pressure in the cultures was maintained until thin blood-smears were parasite-positive (after 7 days). After the negative selection, iRBC were harvested from cultures for genotyping by diagnostic PCR and Southern blot analysis. Subsequently, selected parasites were cloned by limiting dilution as previously described (Marin-Mogollon et al., 2018). Briefly, serial dilutions were performed with uninfected RBC in complete medium (1% hematocrit and 20% serum) and cultured in a total volume of 100 µl incubated in 96-well plates, resulting in 8 rows with the following numbers of iRBC per well: 100, 10, 5, 2.5, 1.25, 0.6, 0.3, 0.15. Plates were incubated in a Candle Jar at 37°C and culture medium was changed every other day. Every 5 days RBC were added resulting in an increase of the hematocrit from 1% to 5%. At days 10 to 11, samples were collected for thick smear analysis from the rows with the highest numbers (100 and 10) of iRBC/well. At day 21 thick smears were made from samples from all rows. Clones were selected from dilutions/row with less than 40% of the wells being parasite-positive. These clones were transferred in 10 ml culture flasks at 5% hematocrit under standard culture conditions in the semi-automated culture system for collection of parasites for further genotype and phenotype analyses (see next section).

Genotyping of Pf-PvCSP Parasites
Diagnostic PCR and Southern blot analysis of digested DNA were performed from material isolated from iRBC obtained from 10 ml cultures, pelleted by centrifugation (1500 g, 5 min). RBC were then lysed with 5 ml of cold (4°C) erythrocyte lysis buffer (10× stock solution 1.5 M NH4Cl, 0.1 M KHCO3, 0.01 M Na2EDTA; pH 7.4; (Janse et al., 2006)) and parasites were treated with proteinase-K before DNA isolation by standard
were dissected and homogenized using a grinder in 100 µl of counting sporozoites, salivary glands from 30 mosquitoes were pelleted by centrifugation (9485 g; 30 s) and stained with Giemsa. For determination of the course of parasitemia, triplicate culture was maintained for a period of 3 days without refreshing medium at a hematocrit of 5%. Medium was changed twice daily and the growth rate of asexual blood stages of the *P. falciparum* strain NF54 was determined in 10 ml cultures maintained in the semi-automated culture system under standard culture conditions. Briefly, a culture with 0.1% parasitemia was established in complete culture medium RPMI pH 7.2 and sporozoites were analyzed in a Bürker cell counter using phase-contrast microscopy.

**Analysis of PvCSP-chi and PfCSP Expression in Sporozoites**

To analyze CSP expression in fixed *Pf*-PvCSP and WT *Pf*NF54 salivary gland sporozoites by indirect immunofluorescence assay (IFA), samples of purified salivary gland sporozoites (20 µl) were placed on a 8-well black cell-line diagnostic microscope slide (Thermo Scientific, NL), dried for 10 min, and fixed with 4% paraformaldehyde for 30 min at room temperature. After fixation the slides were washed three times with PBS and permeabilized with 20 µl of 0.5% triton in PBS and then blocked with 10% of FCS in PBS for 1h. Fixed cells were washed with PBS and incubated overnight at 4°C with the following monoclonal CSP antibodies: mouse anti-*PfCSP* (mAb 2A10, MRA-183; 1:200 dilution of 1 mg/ml stock solution); mouse anti-*PvCSP* VK210 (mAb 2F2; MRA-184; (Salman et al., 2017); 1:200 dilution of 109 µg/ml stock solution) and mouse anti-*PvCSP* VK247 (mAb 2E10.E9; MRA-185; (Salman et al., 2017); 1:200 dilution of 125 µg/ml stock solution. Subsequently, cells were rinsed three times with PBS and incubated with the secondary antibodies Alexa Fluor®488/594-conjugated chicken anti-mouse (Invitrogen Detection technologies, NL at 1:500 dilution). Finally, the cells were washed again three times with PBS and stained with the DNA-specific dye Hoechst-33342 at 1:500 dilution. The slides were dried for 10 min, and sealed with nail polish. Stained cells were analyzed for fluorescence using a Leica fluorescence MDR microscope (100x magnification). Pictures were recorded with a DC500 digital camera microscope using Leica LAS X software with the following exposure times: Alexa 488: 1.0 s; Alexa 594: 0.6 s; Hoechst 0.2 s; bright field 0.62 s (1× gain) or with a Leica SP8 upright confocal microscope.

To analyze CSP expression of live *Pf*-PvCSP and WT *Pf*NF54 salivary gland sporozoites by indirect immunofluorescence assay (IFA), samples of 2 × 10^7 salivary gland sporozoites were aliquoted in 1.5 ml Eppendorf tubes and were incubated with the corresponding antibody (mouse anti-*PfCSP*, mouse anti-*PvCSP* VK210 or mouse anti-*PvCSP*VK247 (1:100 dilution) in 100 µl of 1% (v/v) FCS in PBS 1×, for 1 h on ice. Subsequently, sporozoites were rinsed with 1.5 ml of 1% (v/v) FCS in PBS and pelleted by centrifugation at 9300 g for 4 min at 4°C. The sporozoite pellet was then resuspended in 100 µl 1% FCS in PBS containing the secondary antibodies; anti–mouse IgG Alexa 488 (1:200) and incubated for 1 h on ice. Sporozoites were rinsed with 1.5 ml of 1% (v/v) FCS in PBS and pelleted by centrifugation at 9300 g for 4 min at 4°C, and the resulting pellet was resuspended in 40 µl of PBS. Of the cell suspension containing sporozoites 20 µl was placed per well of an 8-well black cell-line diagnostic microscope slide (Thermo Scientific), incubated 30 min at room temperature (RT), and fixed with 80 µl of 4% PFA in PBS 1× for 30 min at RT. Finally, the wells were washed twice with PBS and stained with 10 µM Hoechst 33342 in PBS for 15 min at RT. For microscopy analysis, the preparations were analyzed using a Zeiss Axioskop epifluorescence microscope equipped with a DP70 camera and AxioVision software. CSP and WT *PfCSP* expression was monitored in sporozoites using anti-CSP VK210 or mouse anti-*PvCSP* (mAb 2F2; MRA-184; (Salman et al., 2017) antibody and Alexa Fluor®488-conjugated chicken anti-mouse (Invitrogen Detection technologies, NL at 1:200 dilution). The slides were washed three times with PBS and stained with the DNA-specific dye Hoechst-33342 at 1:500 dilution. The slides were dried for 10 min, and sealed with nail polish. Stained cells were analyzed for fluorescence using a Leica fluorescence MDR microscope (100x magnification). Pictures were recorded with a DC500 digital camera microscope using Leica LAS X software with the following exposure times: Alexa 488: 1.0 s; Alexa 594: 0.6 s; Hoechst 0.2 s; bright field 0.62 s (1× gain) or with a Leica SP8 upright confocal microscope.

**Phenotype analysis Pf-PvCSP parasites: blood stages, gametocytes, oocysts, and sporozoites**

The growth rate of asexual blood stages of the *Pf*-PvCSP was determined in 10 ml cultures maintained in the semi-automated culture system under standard culture conditions. Briefly, a culture with 0.1% parasitemia was established in complete culture medium at a hematocrit of 5%. Medium was changed twice daily and the culture was maintained for a period of 3 days without refreshing RBC. For determination of the course of parasitemia, triplicate samples of 100 µl were collected daily from all cultures and cells pelleted by centrifugation (9485 g; 30 s) and stained with Giemsa. *P. falciparum* gametocytes cultures were generated using standard culture conditions as previously described (Marin-Mogollon et al., 2018) with some modifications. Briefly, parasites from asexual stage cultures were diluted to a final parasitemia of 0.5%, and cultures were followed during 14 days without adding new RBC. At day 14, gametocyte development was analyzed by counting male/female gametocytes (stage V) in Giemsa stained blood smears. To assess exflagellation, 20 µl samples of the *P. falciparum* gametocyte cultures at day 14 were diluted 1:1 with Fetal Calf Serum (FCS) at room temperature and exflagellation centers were examined and quantified 10–20 min after activation in a Bürker cell counter.

For analysis of oocyst and sporozoite production, *A. stephensi* mosquitoes were fed when cultures contained mature stage V gametocytes and showed more than 80 exflagellating parasites per 10^5 erythrocytes. Mosquito feeding was performed using the standard membrane feeding assay (SMFA) (Ponnudurai et al., 1989). Oocysts were analyzed between day 10 and 12 and salivary gland sporozoites were counted at day 18 and 21 after feeding. Oocyst were counted in 10–30 midguts, dissected in a droplet of mercurochrome (1%) in distilled water on a glass slide. Midguts were covered with a coverslip and oocyst images were recorded from dissected midgut in PBS 1× (100x magnification). For counting sporozoites, salivary glands from 30–60 mosquitoes were dissected and homogenized using a grinder in 100 µl of phenol-chloroform methods. Correct integration of the donor construct was analyzed by long-range PCR (LR-PCR) (primers P1/P3) and standard PCR amplification of the PvCsp-chi gene (primers P4/P5), the PfP47 gene (primers P6/P7) and the fragment for 5’ integration (5’int; primers P1/P2). The PCR fragments were amplified using KOD Hot start polymerase following standard conditions with an annealing temperature of 52°C for 15 s, 55°C for 15 s, and 63°C for 25 s and an elongation step of 68°C for 4 min for LR-PCR and with an annealing temperature of 50°C for 10 s, 55°C for 10 s, and 60°C for 10 s and an elongation step of 68°C for 1 min for the other PCRs. Southern blot analysis was performed with genomic DNA digested with HpaI and EcoRI (4 h at 37°C) to confirm integration of the replacement of the PfP47 gene by the PvCsp-chi expression cassette. Digested DNA was hybridized with probes targeting the PfP47 homology region 1 (HR1), amplified from WT PfNF54 genomic DNA by PCR using the primers P8/P9 and a second probe targeting ampicillin (Amp) gene, amplified from plasmid pLf0109 by PCR using the primers P10/P11.
covered with 1–2 drops of an anti-fading agent (Image-iT™ FX, Life technologies), and a coverslip was placed onto the cells and sealed with nail polish. Stained cells were analyzed for fluorescence using a Leica fluorescence MDR microscope (100× magnification). Pictures were recorded with a DC500 digital camera microscope using Leica LAS X software with the following exposure times: Alexa 488: 0.7 s; Hoechst 0.136 s; bright field 0.62 s (1× gain).

**Sporozoite Gliding Assay**

Sporozoite motility was determined using a sporozoite gliding assay (Stewart and Vanderberg, 1988; van Schaijk et al., 2008). Glass slides were placed in a 24 wells plate (Thermofisher, DK) and coated with an anti-PfCSP monoclonal 3SP2 (courtesy of Dr. M. McCall, Radboudumc, The Netherlands; 5 µg/ml in PBS) using 200 µl per slide, and left overnight at RT. The next day freshly isolated WT PfNF54 and Pf-PvCSP sporozoites, collected in RPMI (Thermofisher, Gibco 42401-018) with 10% FCS (Capricornscientific, FBS-12A CP15-1439) at RT were added to anti-PfCSP coated slides that were washed with PBS. Per slide 30,000 sporozoites were added (in 200 µl RPMI with 10% FCS) and these glass slides were incubated for 2.5 h at 37°C under 5% CO2 conditions. Slides were then washed three times with PBS and fixed with 4% PFA (Thermo Scientific, NL) for 20 min at RT. Then, the slides were washed three times with PBS and blocked with 1% BSA (Roche diagnostic, DE) in PBS for 15 min. After BSA blocking, the slides were washed three times with PBS, and the primary antibody anti-Pf-3SP2 or anti-PvCSP-VK210 Mab (mAb 2F2) (10 µg/ml) was added and incubated for 45 min at RT. Slides were then washed three times with PBS, and incubated with a secondary antibody goat anti-mouse Alexa fluor 488 (Invitrogen Thermofisher, Oregon, A11001) Mab (diluted 500 times in PBS) for 45 min (RT, in the dark). Finally, slides were washed three times with PBS in the dark, air dried until the slides were almost dry and mounted with Coverslips (with Image-iT FX signal Enhancer; Invitrogen Thermo Shér, USA) and examined with a fluorescent microscope with standard GFP field. The percentage of gliding was calculated in 8 fields, measuring the number of gliding trails for the WT PfNF54 sporozoites in comparison with the gliding trails for the Pf-PvCSP sporozoites. The mean and standard deviation were determined for the percentage of gliding trail sporozoites.

**In Vitro Infection of Primary Human Hepatocytes by Sporozoites**

*In vitro* primary human hepatocyte maturation assay was performed as described in (Marin-Mogollon et al., 2019) with few adaptations. Cryopreserved primary human hepatocytes, obtained from Xenothech, were thawed according to the manufacturer and seeded at a density of 60,000 cells/well in a collagen-coated 96-well clear-bottomed black plate for 2 days. Medium was refreshed daily (hepatocyte medium: Williams’s E medium supplemented with 10% heat inactivated fetal bovine serum, 1% penicillin-streptomycin, 1% fungizone, 0.1 IU/ml insulin, 70 µM hydrocortisone). Per well, 7 x 10^6 freshly dissected Pf-PvCSP and WT PfNF54 sporozoites were added to the hepatocyte monolayer. After a quick spin (10 min at 1900 g), the plate was incubated at 37°C under 5% CO2. The medium was replaced with fresh hepatocyte culture medium 3 h post-invasion, and daily for 4 days thereafter. Then, hepatocytes were fixed with ice-cold methanol for at least 10 min on ice. A standard IFA was performed using an anti-PfHSP70 primary antibody (StressMarq) with an Alexa fluor 594 (Invitrogen) secondary antibody and DAPI for nuclear staining. High content imaging was performed, using the ImageXpress Pico system (Molecular Devices). Number of parasites, number of hepatocytes and size of parasites were determined using the CRX software (Molecular Devices) and data analyzed using the GraphPad software.

**Rodent Immunization With Sporozoites and Antibody Production**

For generation of sporozoite-extracts for immunization, salivary gland sporozoites were isolated as described in the previous sections. Aliquots of 10^6 sporozoites in 50 µl PBS were made and stored at ~80°C. After two rounds of freezing and thawing, 10^5 sporozoites in 200 µl PBS were used to immunize mice by intravenous injection. Groups of six C57BL/6 mice were immunized three times with sporozoites at a 7-day interval, and blood was collected in heparinized capillaries from all mice by orbital vein puncture 1 day prior to the first and third immunization and one week after the last immunization. Plasma was collected after centrifugation of the blood samples (1500 g for 8 min at 4°C) and stored at ~20°C until further analysis.

For assessment of anti-CSP antibody titers (total IgG), enzyme-linked immunosorbent assays (ELISAs) were performed. High protein-binding capacity 96-well ELISA plates (Nunc MaxiSorp™ flat-bottom) were coated with synthetic peptides (Sigma) based on the repeat sequences of PfCSP and PvCSP. Specifically, plates were coated with peptides with the amino acid sequence (NANP)4NVPDC for PfCSP, the amino sequence GD RAD GQP AGD RAA GQP A for the PvCSP VK210 and the amino sequence ANGAGNQPG ANGAGDQPG for the PvCSP VK247. The plates were coated overnight at 4°C with a peptide concentration of 5 µg/ml in PBS with a volume of 50 µl per well. Plates were washed three times with 0.05% Tween20/BS (PBST) and blocked with 200 µl of PBST with 5% milk for 30 min at RT. Plates were then washed one additional time and plasma samples were diluted 1:50 in 1% milk PBST and a 3-point 1:3 dilution was carried out for each sample. After 3h incubation at RT, plates were washed three times with PBST and incubated for 1h at RT with the secondary antibody, horseradish peroxidase-labelled goat anti-mouse IgG (GE Healthcare UK) at a dilution of 1:2000. After six PBST washes, the reaction was developed by adding BD OptEIA™ TMB Substrate Reagent and incubating for 1 to 5 min at RT, before stopping the reaction by adding 50 µl Stop solution (2N H2SO4). Absorbance was immediately measured at 450 nm using a Tecan Infinite M200 plate reader. Data were analyzed in relation to a standard titration curve of at least 8 points starting a dilution of 1.5u/ml...
of the corresponding mouse monoclonal antibody: mouse anti- PfCSP (mAb 2A10, MRA-183); mouse anti-PvCSP VK210 (mAb 2F2; MRA-184) and mouse anti-PvCSP VK247 (mAb 2E10.E9; MRA-185). All monoclonal antibodies were produced from hybridoma cell lines obtained from BEI Resources, NIAID, and kindly provided by Elizabeth Nardin.

Statistics
Data were analyzed using GraphPad Prism software version 8.1.1 (GraphPad Software, Inc.). Significance difference analyses between WT PfNF54 and Pf-PvCSP lines were performed using the unpaired Student’s t-test. The value of p < 0.05 was considered statistically significant (* p < 0.01, ** p < 0.001, *** p < 0.0001).

RESULTS

Generation of Chimeric Plasmodium falciparum Sporozoites Expressing PfCSP and Chimeric PvCSP

We have previously shown that chimeric P. falciparum parasites with the PfCsp gene replaced by the two major PvCsp alleles, VK210 and VK247, do not produce salivary gland sporozoites and most oocysts degenerate before formation of sporozoites (Marin-Mogollon et al., 2018). It has been shown that viable and infective rodent P. berghei sporozoites can be engineered to express CSP proteins from two different Plasmodium species. These chimeric sporozoites were generated by introducing a P. falciparum csp gene as an additional copy into the P. berghei genome (Mendes et al., 2018a; Mendes et al., 2018b; Reuling et al., 2020). Based on this observation we aimed at generating chimeric P. falciparum sporozoites expressing both PfCSP and an chimeric PvCSP protein (PvCSP-chi). Using CRISPR/Cas9 gene editing, a chimeric P. falciparum line (Pf-PvCSP) was created that contains the Pvcs-chi gene under the control of 967 bp of the Pfcs gene promoter region. This expression cassette was introduced into the neutral Pfp47 locus (PF3D7_1346800) of the genome of P. falciparum NF54 wild type (WT) parasites. The Pfp47 locus was selected as it is suitable for introducing transgenes without compromising parasite development in the blood and liver stages or in A. stephensi mosquitoes (Talman et al., 2010; Vaughan et al., 2012; Vos et al., 2015; Marin-Mogollon et al., 2019; Miyazaki et al., 2020). The WT PfNF54 parasites were transfected with two plasmids: a previously described construct containing the Cas9 expression cassette with the blastidicin (bsd) drug-selectable marker cassette (pL0019) and a donor DNA construct (pL0109) designed to target the Pfp47 locus. The donor construct contains the Pvcsp-chi expression cassette flanked by two homology regions of Pfp47, the Pfp47 sgRNA sequence and a hdhfr-yfcu drug-selectable marker cassette (see Figures 1A, S1, S2 and Materials and Methods section for details of the generation of the constructs). This Pvcsp-chi gene contains the N- and C-terminal regions of the Pvcsp VK210 allele that flank a chimeric repeat sequence comprising repeats of both the VK210 allele (three times the repeat GDRADGQPA/GDRAAGQPA) and the VK247 allele (three times the repeat ANGAGNQPG/ANGAGDQPG). Transfection of WT PfNF54 parasites was performed using the ‘spontaneous uptake method’. Briefly, uninfected RBC were first transfected with the constructs pL0019 and pL0109. Subsequently, the transfected RBCs were mixed with WT PfNF54 infected RBC (iRBC). Selection of transfected parasites containing both plasmids was performed by applying double-positive selection with the drugs Blastidicin and WR99210 until parasites were detectable by thin blood-smear analysis. Subsequently negative drug selection with 5-fluorocytosine was applied to enrich the parasites in which the Pvcsp-chi gene expression cassette was integrated into the genome by double cross-over homologous recombination. Next drug-selected parasites were cloned by limiting dilution. Diagnostic (long range) PCR and Southern analyses of three clones (Pf-PcPvCSP cl1, cl3, and cl4) confirmed correct double crossover integration of the Pvcsp-chi gene expression into the Pfp47 locus in the genome of all Pf-PvCSP clones (Figures 1B, C). Two Pf-PvCSP clones (cls 1, 3) were selected for further phenotype characterization.

Pf-PvCSP Parasites Produce Sporozoites in Anopheles stephensi Mosquitoes

The in vitro growth of Pf-PvCSP (cl3) blood stages was comparable to that of the parental WT PfNF54 blood stage parasites (Figure 1D). Pf-PvCSP parasites produced numbers of mature gametocytes in standardized gametocyte cultures similar to those of the parental line (Table 1; Figure S3) and male gametocytes underwent exflagellation upon activation. Using SMFA, A. stephensi mosquitoes were infected with gametocytes of either WT PfNF54 or Pf-PvCSP parasites. The number of oocysts in mosquito midguts was determined at days 10 to 12 after infection and the number of sporozoites in salivary glands was analyzed at days 18 to 24 after infection. These analyses revealed that Pf-PvCSP parasites produced comparable number of oocysts and salivary gland sporozoites to those of the parental parasites (Table 1; Figures S3 and S4). Approximately 90% of Pf-PvCSP oocysts already contained sporozoites at days 10 to 12 which is in contrast to the two previously created chimeric P. falciparum lines with the Pkcsp gene replaced by the PvCsp alleles vk210 and vk247. Most of the oocysts of these replacement lines degenerated before the formation of sporozoites (Marin-Mogollon et al., 2018). The presence of Pf-PvCSP sporozoites in salivary glands (Table 1) indicated that PfCSP retains its normal function in the formation of sporozoites, and that expression of PvCSP-chi in these sporozoites does not appear to interfere with sporozoite formation and invasion of salivary glands.

Pf-PvCSP Sporozoites Express PfCSP As Well As PvCSP-chi on Their Surface

To analyze the expression of PvCSP-chi and PfCSP in salivary gland sporozoites of the Pf-PvCSP line, we first performed an immunofluorescence on fixed/permeabilized sporozoites with antibodies specific for the repeat sequences of either PfCSP VK210, PvCSP VK247 or PfCSP. All Pf-PvCSP sporozoites analyzed (n=2 exp.) reacted with all three antibodies whereas WT PfNF54 sporozoites reacted only with anti-PfCSP antibodies (Figure 2), indicating that all Pf-PvCSP sporozoites expressed both the PfCSP and PvCSP-chi proteins.
We next investigated whether PvCSP-chi protein is expressed at the surface of sporozoites, by performing IFA of live salivary gland sporozoites. Similarly to the results of IFA using fixed/permeabilized sporozoites, live Pf-PvCSP sporozoites reacted with anti-PvCSP VK210, anti-PvCSP VK247 and anti-PfCSP antibodies whereas WT PfNF54 sporozoites reacted only to anti-PfCSP antibodies (Figure 3A). This result demonstrates that the PvCSP-chi protein is expressed at the surface of Pf-PvCSP sporozoites.
As CSP is shed during parasite gliding motility, we next assessed if PvCSP is also shed similarly to PfCSP by Pf-PvCSP sporozoites. CSP-trails in a sporozoite gliding assay also reacted with both anti-PfCSP and anti-PvCSP VK210 antibodies (Figure 3B), confirming surface expression of PfCSP-chi and revealing shedding of PfCSP-chi during gliding. Comparable gliding trails were observed in WT PfNF54 and Pf-PvCSP sporozoites using anti-PfCSP antibody (Figure 3B), with a percentage of 85% gliding trails in WT PfNF54 sporozoites (with a range of 28–65 gliding trails per field, Stdev. 2.6) and 87.0% gliding trails in Pf-PvCSP sporozoites (with a range of 23–43 gliding trails per field, Stdev 7.6).

**Pf-PvCSP Sporozoites Infect Primary Human Hepatocytes**

We next assessed the in vitro infectivity of Pf-PvCSP sporozoites to primary human hepatocytes. At day 4 post infection of primary human hepatocytes with either WT or Pf-PvCSP sporozoites, the cells were fixed, and liver stages were stained with an anti-PfHSP70 antibody. Pf-PvCSP sporozoites showed comparable efficiency of hepatocyte infection to WT PfNF54 sporozoites (Figure 4). Pf-PvCSP and WT PfNF54 also displayed similar liver stage sizes at day 4 post infection (Figure 4). These results demonstrate that expression of PfCSP-chi at the surface of Pf-PvCSP sporozoites did not reduce parasite in vitro invasion and development in primary human hepatocytes.

**Immunization of Mice with Pf-PvCSP Sporozoites Induce Antibodies Against Repeats of Both PfCSP and PvCSP-chi**

We then analyzed the capacity of the Pf-PvCSP sporozoites to elicit the production of antibodies against the repeat sequences of PfCSP and PvCSP-chi by immunizing mice with killed Pf-PvCSP and WT PfNF54 sporozoites. Groups of six C57BL/6 mice were intravenously injected with 10⁵ freeze-thaw killed sporozoites, three times with a 7-day interval, and blood was collected from all mice 1 day prior to the first and third immunization and 1 week after the last immunization (Figure 5A). Plasma of these mice was tested for antigen-specific antibody production by ELISA using plates that were coated with the following repeat sequences: (NANP)4NVDPC for PfCSP; GD RAD GQP AGD RAA GQP A for PvCSP VK210; and ANGAGNQPG ANGAGDQPG for PvCSP VK247 strain.

Plasma samples of mice immunized with either WT PfNF54 or Pf-PvCSP sporozoites reacted strongly to the PfCSP repeat sequences after the second and third immunization with no significant differences in total IgG between the two groups of mice (Figure 5B), indicating comparable immunogenicity of the PfCSP repeat sequences in WT PfNF54 or Pf-PvCSP sporozoites. In contrast, only mice immunized with Pf-PvCSP sporozoites showed significantly increased antibody titers specific for the repeat sequences of PfCSP VK210 and PvCSP VK247 whereas no significant increase was observed in WT PfNF54-immunized mice (Figure 5B). Although the total IgG against the PvCSP repeats was lower than that against the PfCSP repeats, these results show that exposure to Pf-PvCSP sporozoites can induce the production of antibodies against PfCSP, as well as against both PvCSP repeat variants.

**DISCUSSION**

In this study we describe a chimeric *P. falciparum* line, Pf-PvCSP, which expresses CSP from both *P. falciparum* and *P. vivax*. We demonstrate that chimeric parasites produce sporozoites in similar numbers to those of the parental WT PfNF54 line and that both CSPs expressed in the chimeric parasites are present at the sporozoite surface and shed during gliding. Our results show that Pf-PvCSP sporozoites are infectious to primary human hepatocytes. These observations support the notion that the presence of the chimeric PvCSP protein at the surface of *P. falciparum* sporozoites does not affect sporozoite viability and infectivity. The formation of infective sporozoites expressing CSP of two different *Plasmodium* species has been previously
demonstrated in studies using P. berghei expressing PfCSP (Mendes et al., 2018b). However, the viability and infectivity of these chimeric Pb-PfCSP sporozoites is expected, since PfCSP can fully complement the multiple functions of PbCSP as shown in replacement P. berghei lines with the endogenous PbCSP replaced by PfCSP (Triller et al., 2017; Flores-Garcia et al., 2019). This is distinct from PvCSP, since previous attempts to functionally complement PfCSP, by replacing the Pfcsp gene with two Pvcsp alleles, were unsuccessful (Marin-Mogollon et al., 2018). It is known that CSP fulfills multiple functions, both in the process of sporozoite formation and in later processes of sporozoite invasion of salivary glands, migration through the human skin and invasion of hepatocytes (Sinnis and Coppi, 2007; Vaughan et al., 2008; Ejigiri and Sinnis, 2009; Coppi et al., 2011; Vaughan and Kappe, 2017).

Although the previously generated gene-replacement Pf-PvCSP parasites were able to produce normal numbers of oocysts, no salivary gland sporozoite were formed and most oocyst degenerated before sporozoite formation, a phenotype that is comparable to P. falciparum mutants lacking the Pfcsp gene (Marin-Mogollon et al., 2018). Collectively, these observations indicate that PvCSP is unable to fully complement the role of PfCSP in the process of sporozoite formation inside oocysts but that the simultaneous expression of PvCSP with PfCSP in sporozoites of chimeric parasites does not hamper the formation of infectious sporozoites. The lack of full complementation of PfCSP by PvCSP in the process of sporozoite formation may result from the inability of PvCSP to interact with other P. falciparum proteins that are involved in (the initial steps of) sporozoite formation.

Our studies of immunization of mice with the chimeric Pf-PvCSP sporozoites shows that antibodies are induced against the repeat sequences of both PfCSP and the PvCSP-chi protein, including antibody responses against both PvCSP alleles, VK210 and VK247. Interestingly, although IgG responses against PfCSP were significantly higher than against PvCSP, anti-PfCSP titers were comparable for mice immunized with either WT PfNF54 sporozoites or Pf-PvCSP sporozoites. These observations indicate that the presence of PvCSP does not affect the immunogenicity of PfCSP with respect to IgG responses against the NANP/NVDP repeats. The lower IgG responses against the two PvCSP repeats compared to the PfCSP NANP/NVDP repeats can be caused by different factors. The PvCSP-chi protein contains only 3 copies of theVK247 and VK210 repeats, while the P. falciparum NF54 CSP protein contains 38 NANP and 4 NVDP repeats (Bowman et al., 1999; Oyen et al., 2018). In addition, although we provide evidence of the presence of PvCSP at the surface of the Pf-PvCSP sporozoites and in gliding trails, the total amount of PfCSP and PvCSP in the Pf-PvCSP sporozoites is unknown and may differ for the two proteins. The lower IgG responses might also result from a lower intrinsic immunogenicity of the PvCSP repeats compared to the P. falciparum NANP/NVDP repeats. The repeat regions of CSP of the P. vivax strains VK210 and VK247 consist of 10–11 copies of the repeats GDR(A/D)GQPA or ANGA (G/D)(N/D)QPG, respectively (de Souza-Neiras et al., 2007) and are not cross reactive (Hall et al., 2019). Of note, our study employed freeze-thaw killed sporozoites to immunize mice; it is
therefore possible that antibody responses against Pf/CSP and Pv/CSP-chi proteins might be different when immunization is performed with live sporozoites.

Despite the differences in the repeat regions of \textit{P. falciparum} and \textit{P. vivax} CSP, both these proteins have been shown to be immunogenic and antibody levels against these repeats appear to be associated with protective immunity in animal malaria models and in humans (Porter et al., 2013; Foquet et al., 2014; Schwenk et al., 2014; Yadava et al., 2014; White et al., 2015; Gimenez et al., 2017; Atcheson et al., 2018; de Camargo et al., 2018; Dobaño et al., 2019).
However, due to differences in methodologies for inducing and analyzing antibody production after immunization with full-length CSP proteins or the respective repeat sequences, the relative immunogenicity of the PfCSP and PvCSP repeats in both animal models and in humans is largely unknown. To our knowledge, no studies exist that have compared the immunogenicity of different CSP repeat sequences of the two human Plasmodium species using similar immunization approaches and delivery systems. In comparative P. vivax and P. falciparum CHMI studies, it has been found that the CSP of both species induced cross-reactive antibodies (Hall et al., 2019). However, it is unknown whether the observed cross-reactivity resulted from the repeat sequences or from other epitopes in the N- or C-terminal region of the CSP molecules. In future studies it will be relevant to analyze infections in the FRG huHep mouse model (repopulated with human RBCs) to show that Pf-PvCSP can form infectious liver merozoites. This would enable the use of this model for testing the efficacy of anti-PvCSP antibodies.

Combined, our observations regarding the expression and immunogenicity of the PvCSP on the surface of P. falciparum sporozoites hold promise for the use of the chimeric Pf-PvCSP sporozoites for clinical evaluation of vaccines targeting PvCSP in clinical CHMI studies. The use of such parasites would bypass the need for P. vivax sporozoite production and measures for hypnozoite removal (Payne et al., 2017). In addition, such chimeric sporozoites might also be used in whole, attenuated sporozoite vaccination approaches (Bijker et al., 2015; Goswami et al., 2020). Vaccination with chimeric, attenuated sporozoites might induce cross-protective immune responses against both P. falciparum and P. vivax.
AUTHOR’S NOTE

This paper is dedicated to the memory of our friend and colleague, SMK, who initiated the studies described in this paper and recently passed away.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

ETHICS STATEMENT

The animal study was reviewed and approved by Animal Experiments Committee Leiden (AVD1160020171625). All experiments were performed in accordance with the Experiments on Animals Act (Wod, 2014), the applicable legislation in the Netherlands and in accordance with the European guidelines (EU directive no. 2010/63/EU) regarding the protection of animals used for scientific purposes.

AUTHOR CONTRIBUTIONS

CM-M, BF-F, CJ, and SMK came up with the study concept and design. YM, CM-M, TI, AM, RL, AS, FG, SM, SC-M, JR, SK, HK, RS, AR-S, MP, CJ, and BF-F acquired the data. YM, CM-M, AM, MP, CJ, and BF-F conducted analysis and interpretation of the data. YM, CM-M, BF-F, and CJ wrote the draft of the manuscript. YM, CM-M, SM, AM, MP, RS, CJ, and BF-F critically revised the manuscript for important intellectual content. AM, KD, BW, and RS provided technical and/or material support. BF-F and CJ supervised the study. All authors reviewed the manuscript. All authors contributed to the article and approved the submitted version.

FUNDING

CM-M was, in part, supported by Colciencias Ph.D. fellowship (Call 568 from 2012 Resolution 01218 Bogota CM-M was, in part, supported by Colciencias Ph.D. fellowship and/or material support. BF-F and CJ supervised the study. All authors reviewed the manuscript. All authors contributed to the article and approved the submitted version.

REFERENCES

Agnandji, S. T., Lell, B., Fernandes, J. F., Abossolo, B. P., Methogo, B. G., Kabwende, A. L., et al. (2012). A phase 3 trial of RTS/S/AS01 malaria vaccine in African infants. N. Engl. J. Med. 367, 2284–2295. doi: 10.1056/NEJMoa1200394

Agnandji, S. T., Fernandes, J. F., Bache, E. B., and Ramharter, M. (2015). Clinical development of RTS/S/AS malaria vaccine: a systematic review of clinical Phase I–III trials. Future Microbiol. 10, 1553–1578. doi: 10.2217/fmb.15.90

Arevalo-Herrera, M., Vasquez-Jimenez, J. M., Lopez-Perez, M., Vallejo, A. F., Amado-Garavito, A. B., Ciespedes, N., et al. (2016). Protective Efficacy of Plasmodium vivax Radiation-Attenuated Sporozoites in Colombian Volunteers: A Randomized Controlled Trial. PLoS Negl. Trop. Dis. 10, e0005070. doi: 10.1371/journal.pntd.0005070

Work performed at IMM was supported by Fundação para a Ciência e Tecnologia (FCT-Portugal)'s grants PTDC/BIB-BMD/2695/2014 and PTDC-SAU-INF-29550-2017. AR-S is supported by the MRC-DPFS grant MR/N019008/1.

ACKNOWLEDGMENTS

We would like to acknowledge Els Baalbergen for the mosquito breeding.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcimb.2020.591046/full#supplementary-material

SUPPLEMENTARY FIGURE 1 | Plasmid maps of plasminins used in this study.

SUPPLEMENTARY FIGURE 2 | Plasmid map of pLM109 and sequence of the commercially synthesized Pvcsp-chi gene. This gene that contains a codon-optimized Pvcsp open reading frame containing the N- and C-terminal regions of the Pvcsp VK210 allele that flank a chimeric repeat sequence comprising repeats of both the VK210 allele (three times the repeat GDRADGQPA/GDRAAGQPA) and the VK247 allele (three times the repeat ANAGAQNGP/ANGAGQDQP3).

SUPPLEMENTARY FIGURE 3 | Percentage of male exflagellating gametocytes and number of oocyst and sporozoites of Pf-PvCSP-chi3 and WT PfNF54 parasites. (A) Percentage of stage V exflagellating male gametocytes in day 14 gametocyte cultures (3 experiments). Each dot correspond to an independent experiment. (B) Number of oocyst per mosquito at day 10 after feeding (n=3). Each dot correspond to the number of oocysts per midgut. (C) Number of sporozoites per mosquito at day 18–24 after feeding (n=3). Each dot corresponds to the mean number of sporozoites per mosquito. Mean and standard error of the mean. n.s., not significant (unpaired t-test; Graphpad).

SUPPLEMENTARY FIGURE 4 | Sporozoite formation in oocysts of Pf-PvCSP and WT PfNF54 parasites. Representative images of oocyst during development (A) and sporozoite formation (B) in oocysts (day 10) from WT NF54 parasites and Pf-PvCSP parasites that express both PCPG and PvCSP-chi. (A) Complete midgut and magnified area (>5). Scale bar: 200 µm (upper row) and 20 µm (lower row). (B) Sporozoite formation in an unstained oocyst. Scale bar: 20 µm.

SUPPLEMENTARY TABLE 1 | Primers used in this study.

Atcheson, E., Bausa, K., Salman, A. M., Alves, E., Blight, J., Viveros-Sandoval, M. E., et al. (2018). Tailoring a Plasmodium vivax Vaccine To Enhance Efficacy through a Combination of a CSP Virus-Like Particle and TRAP Viral Vectors. Infect. Immun. 86, 1–16. doi: 10.1128/IAI.00114-18

Bennett, J. W., Yadava, A., Tosh, D., Sattabongkot, J., Komisar, J., Ware, L. A., et al. (2016). Phase 1/2a Trial of Plasmodium vivax Malaria Vaccine Candidate VMP001/AS01B in Malaria-Naive Adults: Safety, Immunogenicity, and Efficacy. PLoS Negl. Trop. Dis. 10, e0004423. doi: 10.1371/journal.pntd.0004423

Bijker, E. M., Borrmann, S., Kappe, S. H., Mordmuller, B., Sack, B. K., and Khan, S. M. (2013). Novel approaches to whole sporozoite vaccination against malaria. Vaccine 31, 7462–7468. doi: 10.1016/j.vaccine.2013.09.095

Bijker, E. M., Sauerwein, R. W., and Bijker, W. E. (2016). Controlled human malaria infection trials: How tandem block and control construct scientific knowledge. Soc. Sci. Stud. Sci. 46, 56–86. doi: 10.1177/0306327115619784
Bowman, S., Lawson, D., Basham, D., Brown, D., Chillingworth, T., Churcher, C. M., et al. (1999). The complete nucleotide sequence of chromosome 3 of Plasmodium falciparum. Nature 400, 532–538. doi: 10.1038/22964

Clements, J., and Moorthy, V. (2016). Implementation of RTS,S/AS01 Malaria Vaccine—The Need for Further Evidence. N. Engl. J. Med. 374, 2596–2597. doi: 10.1056/NEJMep1606007

Cohen, J., Nussenzwieg, V., Nussenzwieg, R., Vekemans, J., and Leach, A. (2010). From the circumsporozoite protein to the RTS, S/AS candidate vaccine. Hum. Vaccin. 6, 90–96. doi: 10.4161/hv.6.1.9677

Coppi, A., Natarajan, R., Pradel, G., Bennett, B. L., James, E. R., Roggero, M. A., et al. (2011). The malaria circumsporozoite protein has two functional domains, each with distinct roles as sporozoites journey from mosquito to mammalian host. J. Exp. Med. 208, 341–356. doi: 10.1084/jem.20101488

de Camargo, T. M., de Freitas, E. O., Gimenez, A. M., Lima, L. C., De Almeida Caramiko, K., Francisco, K. S., et al. (2018). Prime-boost vaccination with recombinant protein and adenosine-virus expressing Plasmodium vivax circumsporozoite protein (CSP) partially protects mice against Pb/Pv sporozoite challenge. Sci. Rep. 8, 11188. doi: 10.1038/s41598-018-21095-z

Eijigiri, I., and Sinnis, P. (2009). Plasmodium sporozoite-host interactions from the dermis to the hepatocyte. Curr. Opin. Microbiol. 12, 401–407. doi: 10.1016/j.mib.2009.06.006

Espinoza, D. A., Yadava, A., Angov, E., Maurizio, P. L., Ockenhouse, C. F., and Zavala, F. (2013). Development of a chimeric Plasmodium berghei strain expressing the repeat region of the P. vivax circumsporozoite protein for in vivo evaluation of vaccine efficacy. Infect. Immun. 81, 2882–2887. doi: 10.1128/IAI.00461-13

Flores-García, Y., Herrera, S. M., Jhun, H., Pérez-Ramos, D. W., King, C. R., Locke, E., et al. (2019). Optimization of an in vivo model to study immunity to Plasmodium falciparum pre-erythrocytic stages. Malar. J. 18, 426. doi: 10.1186/s12936-019-03055-9

Fouquet, R., Hermsen, C. C., Van Gemert, G. J., Van Breackel, E., Weening, K. E., Sauerwein, R., et al. (2014). Vaccine-induced mononuclear antibodies targeting circumsporozoite protein prevent Plasmodium falciparum infection. J. Clin. Invest. 124, 140–144. doi: 10.1172/JCI70349

Gimenez, A. M., Lima, L. C., Francozo, K. S., Denapoli, P. M. A., Panatieri, R., Bargieri, D. Y., et al. (2017). Vaccine Containing the Three Allelic Variants of the Plasmodium vivax Circumsporozoite Antigen Induces Protection in Mice after Challenge with a Transgenic Rodent Malaria Parasite. Front. Immunol. 8, 1275. doi: 10.3389/fimmu.2017.01275

Goswami, D., Betz, W., Locham, N. K., Parthiban, C., Brager, C., Schäfer, C., et al. (2020). A replication-competent late liver stage-attenuated human malaria parasite. ICI Insight 5 (13). 1–19. doi: 10.1172/ici.insight.135589

Hall, C. E., Hagan, L. M., Bergmann-Leitner, E., Tosh, D. M., Bennett, J. W., Regules, J. A., et al. (2019). Mosquito Bite-Induced Controlled Human Malaria Infection with Plasmodium vivax or P. falciparum Generates Immune Responses to Homologous and Heterologous Preerythrocytic and Erythrocytic Antigens. Infect. Immun. 87, 1–15. doi: 10.1128/IAI.00541-18

Healer, J., Cowman, A. F., Kaslow, D. C., and Birkett, A. J. (2017). Vaccines to Accelerate Malaria Elimination and Eventual Eradication. Cold Spring Harb. Perspect. Med. 7, 1–17. doi: 10.1101/cshperspect.a025627

Hoffman, S. L., Vekemans, J., Richie, T. L., and Duffy, P. E. (2015). The March Toward Malaria Vaccines. Am. J. Prev. Med. 49, S319–S333. doi: 10.1016/j.amepre.2015.09.011

Janse, C. J., Franke-Fayard, B., Mair, G. R., Ramesar, J., Thiel, C., Engelmann, S., et al. (2006). High efficiency transfection of Plasmodium berghei facilitates novel selection procedures. Mol. Biochem. Parasitol. 145, 60–70. doi: 10.1016/j.molbiopara.2005.09.007

Kester, K. E., Cummings, J. F., Ofori-Anyinam, O., Ockenhouse, C. F., Krych, U., Moris, P., et al. (2009). Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults.
Sack, B. K., Miller, J. L., Vaughan, A. M., Douglass, A., Kaushansky, A., Mikolajczak, S., et al. (2014). Model for in vivo assessment of humoral protection against malaria sporozoite challenge by passive transfer of monoclonal antibodies and immune serum. Infect. Immun. 82, 808–817. doi: 10.1128/IAI.01249-13
Salman, A. M., Montoya-Díaz, E., West, H., Lall, A., Atcheson, E., Lopez-Camacho, C., et al. (2017). Rational development of a protective P. vivax vaccine evaluated with transgenic rodent parasite challenge models. Sci. Rep. 7, 46482. doi: 10.1038/srep46482
Sauerwein, R. W., Roestenberg, M., and Moorthy, V. S. (2011). Experimental human challenge infections can accelerate clinical malaria vaccine development. Nat. Rev. Immunol. 11, 57–64. doi: 10.1038/nri2902
Schwenk, R., Debout, M., Porter, M., Nikki, J., Rein, L., Spaccapelo, R., et al. (2014). IgG2 antibodies against a clinical grade Plasmodium falciparum CSP vaccine antigen associate with protection against transgenic sporozoite challenge in mice. PloS One 9, e111020. doi: 10.1371/journal.pone.0111020
Sinnis, P., and Coppi, A. (2007). A long and winding road: the Plasmodium falciparum NF54 strain that expresses GFP-luciferase throughout the parasite life cycle. Mol. Biochem. Parasitol. 186, 143–147. doi: 10.1016/j.molbiopara.2012.10.004
Vijayan, A., Mejías-Pérez, E., Espinosa, D. A., Rama, A., García, C., Sénano, C. O. S., Zavala, F., et al. (2017). A Prime/Boost PICS14K(M)/MVA-PICS(M) Vaccination Protocol Generates Robust CD8(+) T Cell and Antibody Responses to Plasmodium falciparum Circumsporozoite Protein and Protects Mice against Malaria. Clin. Vaccine Immunol. 24, 1–16. doi: 10.1128/CVI.00494-16
Vos, M. W., Stone, W. J., Koolen, K. M., Van Gemert, G. J., Van Schaik, B., Leroy, D., et al. (2015). A semi-automated luminescence based standard membrane feeding assay identifies novel small molecules that inhibit transmission of malaria parasites by mosquitoes. Sci. Rep. 5, 18704. doi: 10.1038/srep18704
White, M. T., Bejon, P., Olotu, A., Griffin, J. T., Riley, E. M., Kester, K. E., et al. (2013). The relationship between RTS,S vaccine-induced antibodies, CD4+ T cell responses and protection against Plasmodium falciparum infection. PLoS One 8, e61395. doi: 10.1371/journal.pone.0061395
White, M. T., Verity, R., Griffin, J. T., Asante, K. P., Owusu-Agyei, S., Greenwood, B., et al. (2015). Immunogenicity of the RTS, S/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trial. Lancet Infect. Dis. 15, 1450–1458. doi: 10.1016/S1473-3099(15)00239-X
Yadava, A., and Waters, N. C. (2017). Rationale for Further Development of a Vaccine Based on the Circumsporozoite Protein of Plasmodium vivax. PLoS Negl. Trop. Dis. 11, e005164. doi: 10.1371/journal.pntd.005164
Yadava, A., Hall, C. E., Sullivan, J. S., Nace, D., Williams, T., Collins, W. E., et al. (2014). Protective efficacy of a Plasmodium vivax circumsporozoite protein-based vaccine in Aotus nancymaae is associated with antibodies to the repeat region. PLoS Negl. Trop. Dis. 8, e3268. doi: 10.1371/journal.pntd.0003268

Conflict of Interest: KD holds stock in TroplQ Health Sciences. RL, AS and KD were employed by TroplQ Health Sciences.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Miyazaki, Marin-Mogollón, Imas, Mendes, van der Laak, Storm, Geurten, Miyazaki, Chevalley-Maurel, Ramesar, Kolli, Kroese, van Schaikenburg, Salmon, Wilder, Reyes-Sandoval, Dechering, Prudêncio, Janse, Khan and Franke-Fayard. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.